SCHEMBL971934

SCHEMBL971934

c1ccc(-c2cc(-c3ccc(-c4c5ccccc5c(-c5ccc6ccccc6c5)c5ccccc45)cc3)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.57
CYP1B1 Q16678 1/20 0.57
MEN1 O00255 8/20 0.53
KMT2A Q03164 8/20 0.53
ALDH1A1 P00352 6/20 0.53
MAPT P10636 5/20 0.53
HPGD P15428 5/20 0.53
NTSR1 P30989 1/20 0.53
KDM4E B2RXH2 4/20 0.47
CYP1A2 P05177 2/20 0.47
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 2/20 0.46
GLA P06280 1/20 0.46
ESR1 P03372 2/20 0.46
ESR2 Q92731 2/20 0.46
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.46
MAOA P21397 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL973879 0.95 CYP1A1 (0.55) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL19009533 0.95 MEN1 (0.54) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL18623340 0.94 CYP1A1 (0.58) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL10301086 0.92 CYP1A1 (0.56) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL19009484 0.92 CYP1A1 (0.53) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL18801255 0.92 CYP1A1 (0.55) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL22766543 0.92 MEN1 (0.51) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL15977478 0.91 CYP1A1 (0.51) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL19271409 0.91 CYP1A1 (0.55) CYP1A1CYP1B1MEN1KMT2AALDH1A1
SCHEMBL15977605 0.91 CYP1A1 (0.51) CYP1A1CYP1B1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7867629-B2 Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2011-01-11 US disclosed
US-20060154105-A1 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same IDEMITSU KOSAN CO., LTD. (JP) 2006-07-13 US disclosed
EP-1582516-A1 NITROGENOUS HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154105-A1 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same L1CAM, NOTCH1, NUDC CYP1A1 1097/4885CYP1B1 1688/4885MEN1 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.